Kaposi's sarcoma associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice

Primary effusion lymphoma (PEL) is an aggressive form of lymphoma that is associated with infection by Kaposi's sarcoma-associated herpesvirus (KSHV). One of the KSHV genes expressed in PE L cells is K13, a potent activator of the NF kappa B pathway. K13 transgenic mice develop lymphomas, but after a long period of latency. A possible candidate that could cooperate with K13 in the development of PE L is c-Myc, whose expression is frequently dysregulated in PEL cells. To study the cooperative interaction between K13 and c-Myc in the pathogenesis of PEL, we crossed the K13 transgenic mice to iMyc(E mu) transgenic mice that overexpress Myc. We report that lymphomas in the K13/iMyc(E mu) double transgenic mice developed with shorter latency and were histologically distinct from those observed in the iMyc(E mu) mice. Lymphomas in the K13/iMyc(E mu) mice also lacked the expression of B-and T-cell markers, thus resembling the immunophenotype of PE L. The accelerated development of lymphoma in the K13/iMyc(E mu) mice was associated with increased expression of K13, elevated NF kappa B activity and decrease in apoptosis. Taken collectively, our results demonstrate a cooperative interaction between the NF kappa B and Myc pathways in lymphomagenesis.